Amsterdam, the Netherlands - Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that in 2024 it was the leading applicant in the field of medical technology at the European Patent Office (EPO), filing 594 Medtech patent applications. This achievement underscores the company's ongoing dedication to transforming healthcare delivery by integrating informatics and AI to improve workflows, enhance the quality of care, and lower costs of care per patient.

The innovations by Philips, which can boast 134 years of innovation history with its research and development programs around the globe, improved the health and well-being of nearly 2 billion people in 2024, keeping it on track towards its target of 2.5 billion lives improved in 2030.

Roy Jakobs, CEO of Royal Philips said: "For more than 130 years, Philips has been at the forefront of innovations improving people's lives. The 2024 European patent rankings show how we continue to innovate in the hospital and the home - helping to deliver better care for more people. To continue driving greater impact, we have shifted our innovation closer to customers. We want to help healthcare professionals improve patient care and empower people everywhere to take care of their health and well-being."

As informatics and AI increasingly create value for healthcare both at the hospital as well as at home, approximately half of the company's R&D investments are focused on these technologies.

Some of the informatics and AI-powered innovations that Philips launched in 2024 include:

- The new Azurion image-guided therapy system with advanced informatics to enhance minimally invasive diagnosis and treatment of stroke and other neurovascular patients.

- FDA-cleared AI tools integrated into the EPIQ CVx and Affiniti CVx ultrasound system to advance cardiovascular imaging and increase automation and productivity, reinforcing Philips' #1 global position in cardiovascular ultrasound.

- The new Philips Spectral CT 7500 RT, enabling personalized radiation therapy planning to deliver better care to more cancer patients.

- FDA approval for the LumiGuide Navigation Wire, which uses fiber optic technology to reduce radiation for both patients and physicians during minimally invasive surgery.

In total, Philips contributed 1,231 European patent applications across various domains, the most of any Dutch company and continuing the company's legacy as one of the top applicants since the EPO started publishing the rankings in 2004.

Further illustrating Philips' innovation leadership is the company's recent inclusion in the Clarivate Top 100 Global Innovators 2025, marking the company's 12th consecutive inclusion in this major assessment of global innovators.

Philips invested approximately EUR 1.7 billion in research and development in 2024 to help drive better care for more people. At more than 9% of sales, this is well above the industry average. The company's extensive intellectual property portfolio includes 50,500 patent rights, 30,500 trademarks, 150,000 design rights, and 3,200 domain names.

For further information, please contact:

Elco van Groningen

Philips Global External Relations

Tel.: +31 6 8103 9584

E-mail: media@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips' patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,800 employees with sales and services in more than 100 countries. News about Philips can be found atwww.philips.com/newscenter.

Attachments

- AI-enabled cardiovascular ultrasound platform

- AI-enabled cardiovascular ultrasound platform

- Lumiguide navigation wire

- Azurion

- Azurion with 3d treatment view

- Spectral CT7500 for RT

COMTEX_463918522/2241/2025-03-25T04:15:03